ImmuCell Corporation (ICCC)
| Market Cap | 75.54M |
| Revenue (ttm) | 27.64M |
| Net Income (ttm) | -1.04M |
| Shares Out | 9.05M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,492 |
| Open | 8.25 |
| Previous Close | 8.25 |
| Day's Range | 8.25 - 8.43 |
| 52-Week Range | 4.52 - 8.46 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Masti... [Read more]
Financial Performance
In 2025, ImmuCell's revenue was $27.64 million, an increase of 4.34% compared to the previous year's $26.49 million. Losses were -$1.04 million, -51.78% less than in 2024.
Financial StatementsNews
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ...
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Earnings Call Transcript: Q4 2025
2025 saw 4.3% sales growth to $27.6M, gross margin rise to 41%, and a $3.3M operating income swing, driven by expanded capacity and a strategic focus on First Defense. Net loss narrowed to $1M despite significant non-cash write-downs.
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that im...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
ImmuCell Earnings Call Transcript: Q4 2025
Strategic focus shifted to First Defense after FDA setbacks for Re-Tain, driving strong domestic sales and operational improvements. Q4 2025 sales reached $7.6M, with Tri-Shield up 41.3% year-over-year, while international sales declined. Asset repurposing and team expansion support future growth.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle healt...
ImmuCell Earnings Call Transcript: Q3 2025
Reported a strong financial turnaround with net income of $1.8 million and gross margin rising to 43% for the nine months ended September 30, 2025. Domestic sales showed positive momentum, and new leadership is focused on operational excellence and growth initiatives.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Announces Onboarding of New CEO and Related Management Changes
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Transcript: Lytham Partners Fall 2025 Investor Conference
Focused on antibody-based products for calf health, the company has doubled manufacturing capacity and achieved strong financial growth in early 2025. Re-Tain, a new non-antibiotic mastitis treatment, is in late-stage FDA review, and leadership transition is planned for year-end.
ImmuCell Announces Selection of its Next President and CEO
PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifi...
ImmuCell Earnings Call Transcript: Q2 2025
Q2 2025 saw strong sales and margin growth, driven by restored First Defense supply and inventory rebuild, though a temporary sales boost is expected to normalize in H2. Re-Tain's commercial launch remains delayed pending FDA approval, with all expiring inventory used for investigational studies.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Announces Bank Debt Refinancing
PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Embarks on CEO Succession Planning Process
PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...
ImmuCell Transcript: Lytham Partners Spring 2025 Investor Conference
Production capacity has doubled, driving strong sales and margin recovery after past disruptions. First Defense now offers broader pathogen coverage and immediate immunity, while Re-Tain is set for investigational use in 2025 as FDA approval is pending.